SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Interpace Biosciences, Inc. IDXG OTC

Other OTC • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Interpace Biosciences, Inc. (IDXG) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $2.20. It has a SharesGrow Score of 85/100, indicating a strong investment profile with 5 out of 7 criteria passed.

Financials: revenue is $39M, +8.5%/yr average growth. Net income is $25M, growing at +372%/yr. Net profit margin is 63.5% (strong). Gross margin is 62.3% (+5 pp trend).

Balance sheet: total debt is $752,000 against $22M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 1.94 (strong liquidity). Debt-to-assets is 2.2%. Total assets: $34M.

Analyst outlook: 6 / 7 analysts rate IDXG as buy (86%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 83/100 (Pass), Past 75/100 (Partial), Health 100/100 (Pass), Moat 50/100 (Partial), Future 90/100 (Pass), Income 100/100 (Pass).

IDXG SharesGrow Score Overview

85/100

SharesGrow Score

Strong investment profile

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 83/100

Financials — average growth

PAST 75/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 50/100

Gross margin is + market cap

FUTURE 90/100

Analyst outlook — as buy

INCOME 100/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — IDXG

IDXG trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

IDXG: +8.5%/yr revenue is, +372%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

IDXG: 3 / 4 years profitable. mixed. Score = 3 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet IDXG: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 1.94 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

IDXG: Gross margin is 62.3% (+5 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.

View details →

Analyst outlook: 6 / 7 analysts rate IDXG as buy (86%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

IDXG: Net profit margin is 63.5%. strong (≥30%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.443-2.01

Volume151

Avg Volume (30D)8.66K

Market Cap$9.73M

Beta (1Y)0.97

Share Statistics

EPS (TTM)5.55

Shares Outstanding$4.42M

IPO Date1998-05-20

Employees111

CEOThomas W. Burnell

Financial Highlights & Ratios

Revenue (TTM)$38.73M

Gross Profit$24.13M

EBITDA$4.76M

Net Income$24.58M

Operating Income$4.08M

Total Cash$2.51M

Total Debt$752K

Net Debt$-1.75M

Total Assets$33.84M

Price / Earnings (P/E)0.4

Price / Sales (P/S)0.25

Analyst Forecast

Rating ConsensusBuy

Analysts Covering7

Buy 86% Hold 14% Sell 0%

Company Info

CountryUS

ExchangeOther OTC

CurrencyUSD

ISINUS46062X3035

Price Chart

IDXG

Interpace Biosciences, Inc. ↗ · Other OTC

Healthcare • Medical - Diagnostics & Research

0.44 52WK RANGE 2.01

People Also View

Olink Holding AB (publ)

Personalis, Inc.

Genetron Holdings Limited

FONAR Corporation

OncoCyte Corporation

Sera Prognostics, Inc.

Burning Rock Biotech Limited

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message